声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 国家知识产权局信息显示，石药集团中奇制药技术（石家庄）有限公司取得一项名为"一种阿瑞匹坦注 射液的体外释放方法"的专利，授权公告号CN117250269B，申请日期为2023年8月。 天眼查资料显示，石药集团中奇制药技术（石家庄）有限公司，成立于2003年，位于石家庄市，是一家 以从事研究和试验发展为主的企业。企业注册资本3975.47万人民币。通过天眼查大数据分析，石药集 团中奇制药技术（石家庄）有限公司共对外投资了6家企业，参与招投标项目13次，专利信息446条，此 外企业还拥有行政许可34个。 作者：情报员 ...

南财智讯12月31日电，博济医药发布公告称，公司全资子公司杏林中医药科技（广州）有限公司近日收 到国家知识产权局颁发的1项《发明专利证书》。专利名称为"一种肝脏靶向烷化剂及其应用"。 ...

Core Viewpoint - Zhejiang Tianyu Pharmaceutical Co., Ltd. has applied for a patent for a preparation method of Azilsartan Ester Potassium Salt, indicating innovation in pharmaceutical manufacturing [1] Company Overview - Zhejiang Tianyu Pharmaceutical Co., Ltd. was established in 2003 and is located in Taizhou, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 3,479.77159 million RMB [1] - The company has invested in 22 enterprises and participated in 20 bidding projects [1] - It holds 9 trademark information and 75 patent information, along with 23 administrative licenses [1] Patent Details - The patent application, published as CN120441565A, was filed on January 2025 [1] - The preparation method involves crystallization of Azilsartan Ester with Potassium Octanoate in an organic solvent at a temperature of 30-50°C, followed by aging treatment for at least 10 hours [1] - The method results in high yield, good purity, low impurity content, and significantly increased potassium ion content, demonstrating good stability [1] - The process conditions are milder, reducing energy consumption and eliminating the need for complex devices, enhancing operational practicality [1]